H P Tony
Overview
Explore the profile of H P Tony including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steinhardt M, Wiebecke S, Weismann D, Frantz S, Tony H, Klinker H, et al.
Scand J Rheumatol
. 2020 Sep;
49(5):414-416.
PMID: 32914670
No abstract available.
2.
Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, et al.
Z Rheumatol
. 2017 Jun;
77(1):28-39.
PMID: 28589389
Background: The German Registry of Autoimmune Diseases 2 (GRAID2) is a retrospective, non-interventional, multicenter registry study collecting data from patients with inflammatory, mainly rheumatic diseases refractory to standard of care...
3.
Henes J, Schulze-Koops H, Witt M, Tony H, Mueller F, Grunke M, et al.
Z Rheumatol
. 2017 May;
77(1):12-20.
PMID: 28536934
Objective: To evaluate the safety and clinical outcome of biological therapies in patients with large vessel vasculitis (LVV) or polymyalgia rheumatica (PMR) refractory to standard of care therapy in a ...
4.
Meissner Y, Richter A, Manger B, Tony H, Wilden E, Listing J, et al.
Ann Rheum Dis
. 2017 May;
76(9):1583-1590.
PMID: 28483768
Objective: In the general population, the incidence of stroke is increased following other serious events and hospitalisation. We investigated the impact of serious adverse events on the risk of stroke...
5.
Kleinert S, Tony H
Internist (Berl)
. 2012 Aug;
53(9):1028-37.
PMID: 22895735
Rheumatic diseases are manifested in all ages. First manifestations of gout are frequent between the ages of 40-60 years. Furthermore, the incidence of rheumatoid arthritis increases as well as anti-neutrophil...
6.
Aringer M, Burkhardt H, Burmester G, Fischer-Betz R, Fleck M, Graninger W, et al.
Lupus
. 2011 Nov;
21(4):386-401.
PMID: 22072024
Systemic lupus erythematosus (SLE) can be a severe and potentially life-threatening disease that often represents a therapeutic challenge because of its heterogeneous organ manifestations. Only glucocorticoids, chloroquine and hydroxychloroquine, azathioprine,...
7.
Emery P, Keystone E, Tony H, Cantagrel A, Vollenhoven R, Sanchez A, et al.
Ann Rheum Dis
. 2008 Jul;
67(11):1516-23.
PMID: 18625622
Objectives: The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF)...
8.
Feuchtenberger M, Kneitz C, Tony H
MMW Fortschr Med
. 2007 Jul;
148(42):44-5, 47.
PMID: 17621799
In the hands of an experienced rheumatologist and in adherence to the contraindications named in the article, anticytokines such asTNF-alpha blockers or interleukin-1 antagonists are regarded as relatively reliable, are...
9.
Kleinert S, Tony H, Kneitz C
Internist (Berl)
. 2006 Sep;
47(10):1051-61.
PMID: 16972070
Systemic sclerosis (SSc; syn. systemic scleroderma) is a rare autoimmune disorder with characteristic cutaneous manifestations. Prevalence in women is fivefold higher than in men. The course of the disease is...
10.
Kneitz C, Tony H, Kruger K
Internist (Berl)
. 2006 Mar;
47(5):533-4, 536-8, 540.
PMID: 16557412
NSAIDs (non steroidal anti-inflammatory drugs) are a crucial component for the therapy of pain induced by inflammatory and degenerative joint diseases. Nevertheless their known therapeutic efficacy is contrasted by significant...